ERBB2 and ovarian cancer: Here we further demonstrate that growth inhibition of ovarian cancer cells is not an accurate metric of HER-targeted drug "responsiveness." Specifically, we demonstrate that long-term trastuzumab treatment of HER2-positive EOC-derived cells confers de novo sensitivity to EGFR-targeted therapeutics, regardless of trastuzumab's ability to inhibit cell growth.